Dr. Rosario Fernández-Godino is an expert in advanced cell models for complex diseases, with a focus on retinal and neurodegenerative disorders. She earned her PhD in Genetics and Cell Biology from the Complutense University of Madrid in 2009, followed by postdoctoral training at INIA (Madrid), the Medical Genome Center (Seville), and later at Mass Eye and Ear–Harvard Medical School, where she became Assistant Professor. During her decade at Harvard, she developed CRISPR-edited iPSC-based models to study Age-related Macular Degeneration (AMD) and inherited retinal diseases. Her work advanced understanding of retinal pigment epithelium (RPE) dysfunction and facilitated innovations in biomarker discovery, drug screening, and gene therapy. In 2019, her research led to a gene therapy for PRPF31-associated Retinitis Pigmentosa, licensed to Biogen. In 2021, she joined a Boston biotech as Retina Program Director, focusing on non-viral gene therapies. Since 2022, she has led Screening and Target Validation at Fundación MEDINA in Spain, managing international programs that apply cutting-edge cell models to drug discovery in cancer, neurodegeneration, and rare genetic disorders. Dr. Fernández-Godino has published over 25 articles, including 10 as corresponding author, and remains a leader in cell-based precision medicine.